Get the Stockscreener App
237.18
2.23%
-5.40
After Hours:
237.18
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $237.18, with a volume of 965.60K.
It is down -2.23% in the last 24 hours and up +0.89% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$242.58
Open:
$242.01
24h Volume:
965.60K
Relative Volume:
1.17
Market Cap:
$34.84B
Revenue:
$4.93B
Net Income/Loss:
$1.25B
P/E Ratio:
28.00
EPS:
8.47
Net Cash Flow:
$1.38B
1W Performance:
-7.94%
1M Performance:
+0.89%
6M Performance:
+8.39%
1Y Performance:
+24.36%
1-Day Range:
$235.09
$243.41
1-Week Range:
$235.00
$259.95
52-Week Range:
$170.56
$263.05
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
237.18 | 34.84B | 4.93B | 1.25B | 1.38B | 8.47 |
|
ISRG
Intuitive Surgical Inc
|
588.50 | 209.89B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.21 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
91.65 | 45.33B | 9.76B | 1.16B | 665.00M | 2.34 |
|
WST
West Pharmaceutical Services Inc
|
330.47 | 23.97B | 2.88B | 499.60M | 321.60M | 6.74 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed (NYSE:RMD) Shares Gap Up on Analyst Upgrade - MarketBeat
ResMed Inc. (NYSE:RMD) Stock Holdings Increased by Spire Wealth Management - MarketBeat
ResMed Inc. (NYSE:RMD) Stock Position Lowered by Oak Family Advisors LLC - MarketBeat
Chicago Partners Investment Group LLC Buys New Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Chicago Capital LLC Buys 3,551 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
abrdn plc Has $84.44 Million Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc Director Plans Sale of 2,000 Shares - MSN
Capital Investment Services of America Inc. Sells 1,961 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. Reports Changes in CDI and Security Issuances - MSN
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus.com
Cibc World Market Inc. Increases Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
Looking to bag the record high ResMed dividend? You better hurry! - MSN
ResMed Inc. (NYSE:RMD) Director Sells $484,220.00 in Stock - MarketBeat
ResMed Inc. Announces Changes in Beneficial Ownership - TipRanks
Jericho Financial LLP Makes New Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
FY2025 Earnings Forecast for ResMed Issued By William Blair - MarketBeat
ResMed (NYSE:RMD) Given New $280.00 Price Target at KeyCorp - MarketBeat
ResMed (NYSE:RMD) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" - MSN
ResMed (NYSE:RMD) Given New $286.00 Price Target at JPMorgan Chase & Co. - MarketBeat
ResMed: Digital Health Drives Q2 Growth - MSN
BDF Gestion Sells 1,532 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Resmed Incorporated's Fiscal 2Q Revenue, NPAT Results Above Consensus; Jarden Research Says - Marketscreener.com
Zacks Research Issues Optimistic Outlook for ResMed Earnings - MarketBeat
ResMed Inc. (NYSE:RMD) Declares $0.53 Quarterly Dividend - MarketBeat
ResMed (NYSE:RMD) Earns Hold Rating from Needham & Company LLC - MarketBeat
Morgans rates RMD as Add -February 03, 2025 at 06:33 pm EST - Marketscreener.com
Piper Sandler raises ResMed stock price target to $260 - MSN
ResMed (NYSE:RMD) Reaches New 52-Week High After Strong Earnings - MarketBeat
Resmed Inc Officer Files Notice for Stock Sale - TipRanks
ResMed (NYSE:RMD) Issues Quarterly Earnings Results - MarketBeat
Stifel maintains ResMed stock hold rating, $250 target - MSN
ResMed’s SWOT analysis: sleep tech giant faces GLP-1 drug challenge - Investing.com Nigeria
ResMed’s half-year FY25 results: solid growth & expanding opportunities - Roger Montgomery
ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge By Investing.com - Investing.com South Africa
ResMed (RMD technical analysisResMed (NYSE:RMD) - Benzinga
Here's Why ResMed (RMD) is a Strong Momentum Stock - Yahoo Finance
Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014. - Marketscreener.com
ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge - Investing.com
ResMed (NYSE:RMD) Price Target Raised to $280.00 - Defense World
ResMed’s (RMD) “Hold” Rating Reiterated at Needham & Company LLC - Defense World
ResMed (NYSE:RMD) Price Target Raised to $260.00 - Defense World
ResMed Inc. (NYSE:RMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
ResMed (NYSE:RMD) Price Target Raised to $286.00 - Defense World
ASX 200 reporting season: ResMed - IG
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It? - MSN
ResMed stock soars to 52-week high, reaching $260.71 - MSN
Down 4%, is the ResMed share price in the buy zone? - MSN
ResMed (NYSE:RMD) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
ResMed beats quarterly profit estimates on demand for sleep disorder devices - MSN
ResMed Inc. Reports Steady Compliance and Market Position - TipRanks
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.98%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):